NCCN Says Comparative Effectiveness in Oncology Won't Clash With Personalized Rx

In a draft paper, entitled "The NCCN Comparative Therapeutic Index as a Paradigm for Near-Term Comparative Effectiveness Analyses of Existing Data in Oncology," the NCCN said its methodologies for comparing the risk/benefit value of treatments "will not be in conflict with 'personalized medicine' as it pertains to the care of cancer patients."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.